The spatial folding of chromosomes inside the nucleus has regulatory effects on gene expression, yet the impact of genome reshuffling on this organization remains unclear. Here, we take advantage of chromosome conformation capture in combination with single-nucleotide polymorphism (SNP) genotyping and analysis of crossover events to study how the higher-order chromatin organization and recombination landscapes are affected by chromosomal fusions in the mammalian germ line.
We demonstrate that chromosomal fusions alter the nuclear architecture during meiosis, including an increased rate of heterologous interactions in primary spermatocytes, and alterations in both chromosome synapsis and axis length.
These disturbances in topology were associated with changes in genomic landscapes of recombination, resulting in detectable genomic footprints. Overall, we show that chromosomal fusions impact the dynamic genome topology of germ cells in two ways: (i) altering chromosomal nuclear occupancy and synapsis, and (ii) reshaping landscapes of recombination.
Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection
Head and neck squamous cell carcinoma (HNSCC) are the sixth most common cancer type in the world. Human papillomavirus (HPV) infection is an emerging risk factor for HNSCC. Immune infiltration of HNSCC is linked to therapeutic results. This article aimed to decide whether variations in HPV status affect immune infiltration, molecular mechanism, and how these results vary in HNSCC patients.
We investigated the tumor-infiltrating immune cells (TIICs) and immune-related gene differences between HPV (+) and HPV (-) HNSCC. The gene expression quantification data of HNSCC and their clinical information were download from the TCGA database. Immune-related genes have been linked to the ImmPort platform.
After analyzed of 22 TIICs in the HNSCC tumor environment by CIBERSORT and further assessment, lower memory B cell and higher T cell regulatory were connected with better HPV (-) HNSCC outcome, higher activated memory CD4 T cell, higher T cell regulatory, and lower activated NK cell were linked with better HPV (+) result.
We finally got five forms of immune genes (CAMP, EDNRB, NTS, CXCL9, LHB) associated with HNSCC progression. Higher expressions of CAMP, EDNRB, and NTS were associated with increased overall survival in HPV (-) patients. Higher expression of CXCL9 and lower expression of LHB contributed to increased overall survival of HPV (+) patients.
There tend to be discrepancies in the cell structure of TIICs and immune-related genes in HPV (-) and HPV (+) HNSCC. These variances are typically too crucial for the therapeutic outcome of the patient and the development of the tumor. In specific, our sample established these candidate immune cells and immune-related genes as candidate reservoirs for further researches.
Multi-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage
The evolutionary pressure of endemic malaria and other erythrocytic pathogens has shaped variation in genes encoding erythrocyte structural and functional proteins, influencing responses to hemolytic stress during transfusion and disease.
We sought to identify such genetic variants in blood donors by conducting a genome-wide association study (GWAS) of 12,353 volunteer donors, including 1,483 African Americans, 1,477 Asians, and 960 Hispanics, whose stored erythrocytes were characterized by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis.
GWAS revealed 27 significant loci (p<5×10-8), many in candidate genes known to modulate erythrocyte structure, metabolism, and ion channels, including SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/Band 3. GWAS of oxidative hemolysis identified variants in antioxidant enzymes including GLRX, GPX4, G6PD, and a novel golgi-transport protein SEC14L4.
Genome wide significant loci were also tested for association with the severity of steady state (baseline) in vivo hemolytic anemia in patients with sickle cell disease, with confirmation of identified SNPs in HBA2, G6PD, PIEZO1, AQP1 and SEC14L4. Many of the identified variants, such as those in G6PD, have previously been shown to impair erythrocyte recovery after transfusion, associate with anemia, or cause rare Mendelian human hemolytic diseases.
Candidate SNPs in these genes, especially in polygenic combinations, may affect RBC recovery after transfusion and modulate disease severity in hemolytic diseases, such as sickle cell disease and malaria.

stjosephs-hospital
Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer
Background: Treatment of patients with luminal metastatic breast cancer (MBC) has become even more complex over the last few years as molecular profiling has begun to alter disease management. It is well accepted that MBC is not curable but is treatable. Today we are able to prolong progression-free survival and partly overall survival with targeted and more individual treatment strategies adjusted according to the molecular subtype.
Summary: Genetic and genomic testing has become therapeutically relevant in luminal MBC and is therefore an integral component within the treatment spectrum. By now, germline testing of BRCABRCAPIK3CA mutations are inevitable elements in disease management and the current state of the art in luminal MBC patients.
Furthermore, testing of ESR1 resistance mutation, ERBB2 mutation, microsatellite instability, and neurotrophic tyrosine receptor kinase (NTRK) gene fusion (mainly in secretory breast cancer) has recently gained increasing attention. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities. The following review summarizes current developments in genetic and genomic testing in luminal MBC.
Key messages: In luminal MBC genomics have become an integral component within the spectrum of oncological treatment establishing novel therapeutic facilities. Further developments in treatment personalization adjusted according to the molecular subtype should become increasingly important in order to enhance the progress of de-escalation of chemotherapy in luminal MBC. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities.
HIV-P24 antigen array kit |
VArk-Lsx001 |
Creative Biolabs |
unit |
Ask for price |
Description: Fourth-generation HIV immunoassays detect viral p24 protein in the blood. |
HIV-1 p17-p24 recombinant antigen. |
00172-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 p17-p24 recombinant antigen. |
HIV-1 GAG P24 Recombinant Antigen |
00111-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 GAG P24 Recombinant Antigen |
00111-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV 1 p24 core recombinant antigen |
00177-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV 1 p24 core recombinant antigen. |
HIV 1 p24 core recombinant antigen |
00177-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV 1 p24 core recombinant antigen. |
HIV 1 p24 core recombinant antigen. |
00177-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV 1 p24 core recombinant antigen. |
HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
0801200 |
Zeptometrix |
5 X 96T |
EUR 2563 |
HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
801200 |
Zeptometrix |
5 X 96 Determinations |
EUR 2330 |
HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations) |
801008 |
Zeptometrix |
5 X 96 Determinations |
EUR 2386 |
HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations) |
0801008 |
Zeptometrix |
5 X 96T |
EUR 2505 |
Human HIV(1+2 antibodies plus p24 antigen (4th Generation) ELISA Kit |
EH4101 |
FN Test |
96T |
EUR 571.5 |
|
Description: Method of detection: Qualitative ;Reacts with: Homo sapiens;Sensitivity: Qualitative |
HIV-1 p24 ELISA Kit |
Z7040001 |
Biochain |
1 kit |
EUR 752 |
HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
00111-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 p17/24/gp120 antigen |
00169-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV-1 p17/24/gp120 antigen |
00169-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV-1 intergase antigen |
00199-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). |
HIV-1 intergase antigen |
00199-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase). |
HIV-1 p24 Antibody |
20-abx137062 |
Abbexa |
|
|
|
HIV-1 p24 Antibody |
7313-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
HIV-1 p24 Antibody |
7313-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
HIV-1 p24 Antibody |
abx021869-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021870-1mg |
Abbexa |
1 mg |
EUR 760.8 |
|
HIV-1 p24 Antibody |
abx021871-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021872-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021873-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
HIV-1 p24 Antibody |
abx021882-1mg |
Abbexa |
1 mg |
EUR 1178.4 |
|
HIV-1 p24 Antibody |
abx021883-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx021886-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx021887-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx021888-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
HIV-1 p24 Antibody |
abx023027-1ml |
Abbexa |
1 ml |
EUR 693.6 |
|
HIV-1 p24 Antibody |
abx023925-1mg |
Abbexa |
1 mg |
EUR 828 |
|
HIV-1 p24 Antibody |
abx023926-1mg |
Abbexa |
1 mg |
EUR 828 |
|
HIV-1 p24 |
E5-00024 |
EnoGene |
1mg |
EUR 1152 |
HIV-1 p24 |
E62H002 |
EnoGene |
100ug |
EUR 458.4 |
HIV-1 tat recombinant antigen |
00110-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 tat recombinant antigen |
00110-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 nef recombinant antigen |
00112-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 nef recombinant antigen |
00112-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 gag recombinant antigen |
8934 |
Virostat |
100 ug |
EUR 542.86 |
Description: This is HIV-1 gag recombinant antigen for ELISA,WB. |
HIV-1 nef recombinant antigen |
8941 |
Virostat |
100 ug |
EUR 477.6 |
Description: This is HIV-1 nef recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen, |
00170-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 recombinant antigen, |
00170-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 gp41 recombinant antigen. |
HIV-1 gp41 recombinant antigen |
8908 |
Virostat |
100 ug |
EUR 673.36 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
8933 |
Virostat |
100 ug |
EUR 477.6 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
9000 |
Virostat |
100 ug |
EUR 484.13 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen |
9001 |
Virostat |
100 ug |
EUR 484.13 |
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB. |
HIV-1 gp41 recombinant antigen. |
00170-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 gp41 recombinant antigen. |
HIV p24 Antibody |
abx021867-1mg |
Abbexa |
1 mg |
EUR 1612.8 |
|
HIV p24 Antibody |
abx021868-1mg |
Abbexa |
1 mg |
EUR 1612.8 |
|
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
00168-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120-gp41 recombinant antigen, |
00168-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV-1 p17/24/gp120-gp41 recombinant antigen. |
00168-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen. |
HIV 1 envelope recombinant antigen |
00176-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
HIV 1 envelope recombinant antigen |
00176-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41. |
ToX Antigen (P24,GRA1) |
E61Y00305 |
EnoGene |
1mg |
EUR 840 |
HIV-1 p24 Antibody (HRP) |
abx023029-1ml |
Abbexa |
1 ml |
EUR 886.8 |
|
HIV-1 p24 Antibody [8G9] |
PM-6335-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] |
PM-6335-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] |
PM-6585-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] |
PM-6585-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 env gp41 recombinant antigen |
00113-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-1 env gp41 recombinant antigen |
00113-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-1 p24 Antibody (FITC) |
abx021884-100ug |
Abbexa |
100 ug |
EUR 886.8 |
|
HIV-1 p24 Antibody (FITC) |
abx023026-1ml |
Abbexa |
1 ml |
EUR 678 |
|
HIV 1 / 2 p24 Antibody |
abx021866-1mg |
Abbexa |
1 mg |
EUR 1212 |
|
HIV 1 / 2 p24 Antibody |
abx021890-1mg |
Abbexa |
1 mg |
EUR 1212 |
|
HIV-1 gp41 Long recombinant antigen, |
00171-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-1 gp41 Long recombinant antigen, |
00171-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-1 gp41 Long recombinant antigen. |
00171-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 gp41 Long recombinant antigen. |
HIV-1 p24 Antibody (Biotin) |
abx023028-1ml |
Abbexa |
1 ml |
EUR 794.4 |
|
Polyclonal HIV-1 p24 Antibody |
APR11116G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human HIV-1 p24 . This antibody is tested and proven to work in the following applications: |
HIV-1 p24 Protein |
20-abx261886 |
Abbexa |
-
EUR 5388.00
-
EUR 393.60
-
EUR 276.00
|
|
|
HIV-1 p24 Protein |
abx169032-1mg |
Abbexa |
1 mg |
EUR 661.2 |
|
HIV-1 p24 Protein |
abx061424-05mg |
Abbexa |
0.5 mg |
EUR 886.8 |
|
HIV-1, p24 Protein |
abx069857-1mg |
Abbexa |
1 mg |
EUR 1888.8 |
|
HIV-1 Gag p24 |
05-005 |
Sceti |
50 ug |
EUR 434.4 |
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
HIV-1 Gag p24 |
05-006 |
Sceti |
250 ug |
EUR 1154.4 |
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
HIV 1 p24 Protein |
abx060589-1mg |
Abbexa |
1 mg |
EUR 1545.6 |
|
HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
00169-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120. |
HIV 1, 2 envelope recombinant antigen |
00175-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV 1, 2 envelope recombinant antigen |
00175-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV-1 reverse transcriptase recombinant antigen |
00198-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-1 reverse transcriptase recombinant antigen. |
HIV-1 reverse transcriptase recombinant antigen |
00198-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-1 reverse transcriptase recombinant antigen. |
HIV-1 reverse transcriptase recombinant antigen. |
00198-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 reverse transcriptase recombinant antigen. |
Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody |
abx411336-02mg |
Abbexa |
0.2 mg |
EUR 710.4 |
|
Feline Immunodeficiency Virus p24 Antigen (FIV p24) Antibody |
abx412988-2ml |
Abbexa |
2 ml |
EUR 727.2 |
|
HIV Type-1 p24 Antibody |
V2344-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV Type-1 p24 Antibody |
V2344-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV Type-1 p24 Antibody |
V2344CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 349.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV Type-1 p24 Antibody |
V2344SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load. |
HIV-2 gp32 recombinant antigen |
00173-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV-2 gp32 recombinant antigen. . |
HIV-2 gp32 recombinant antigen |
00173-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV-2 gp32 recombinant antigen. . |
HIV-2 gp36 recombinant antigen |
8911 |
Virostat |
100 ug |
EUR 673.36 |
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp36 recombinant antigen |
8949 |
Virostat |
100 ug |
EUR 529.8 |
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp36 recombinant antigen |
9003 |
Virostat |
100 ug |
EUR 484.13 |
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp32 recombinant antigen. . |
00173-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-2 gp32 recombinant antigen. . |
HIV-1 p24 Antibody [8G9] (HRP) |
PM-6335-HRP-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] (HRP) |
PM-6335-HRP-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (HRP) |
PM-6585-HRP-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (HRP) |
PM-6585-HRP-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] (biotin) |
PM-6335-biotin-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [8G9] (biotin) |
PM-6335-biotin-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (biotin) |
PM-6585-biotin-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV-1 p24 Antibody [7F4] (biotin) |
PM-6585-biotin-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3). |
HIV type O envelope antigen |
00178-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV type O envelope antigen |
00178-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
HIV 2 gp36 envelope antigen |
00180-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
HIV 2 gp36 envelope antigen |
00180-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
Polyclonal HIV-1 p24 Antibody [7F4] |
APR11117G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Mouse that recognizes and binds to Human HIV-1 p24 [7F4] . This antibody is tested and proven to work in the following applications: |
HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
00175-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide. |
HIV-2 GP 36 Recombinant Antigen |
00114-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
HIV-2 GP 36 Recombinant Antigen |
00114-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
HIV-1 p24, His tag |
E410A26-20 |
EnoGene |
20μg |
EUR 520.8 |
HIV-1 p24 Core Protein |
20-abx260141 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
Mouse antibody for HIV-1 p24 |
1941 |
Virostat |
100 ug |
EUR 399.3 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
1946 |
Virostat |
100 ug |
EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
1947 |
Virostat |
100 ug |
EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
1948 |
Virostat |
100 ug |
EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Mouse antibody for HIV-1 p24 |
1949 |
Virostat |
100 ug |
EUR 425.4 |
Description: This is purified Mouse monoclonal antibody against HIV-1 p24 for WB, ELISA. |
Recombinant HIV-1 p24 Core |
7-07599 |
CHI Scientific |
1000µg |
Ask for price |
QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA) |
VPK-108-H |
Cell Biolabs |
96 assays |
EUR 866.4 |
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation. |
QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA) |
VPK-108-H-5 |
Cell Biolabs |
5 x 96 assays |
EUR 3560.4 |
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation. |
Recombinant HIV-1 p24 , 24kDa |
7-07621 |
CHI Scientific |
2µg |
Ask for price |
Recombinant HIV-1 p24 , 24kDa |
7-07622 |
CHI Scientific |
10µg |
Ask for price |
Recombinant HIV-1 p24 , 24kDa |
7-07623 |
CHI Scientific |
100µg |
Ask for price |
HIV-1 p24 Recombinant Protein |
53-341 |
ProSci |
0.01 mg |
EUR 789.9 |
Description: HIV-1 p24 Recombinant Protein |
HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
00112-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
00113-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV -2 env gp36 recombinant antigen |
00179-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. |
HIV -2 env gp36 recombinant antigen |
00179-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702. |
HIV-1 tat recombinant antigen full length 15 kDa |
00110-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 p24 Immune Complex Dissociation Kit |
Z7040009 |
Biochain |
1 kit |
EUR 122 |
HTLV-I p24 core recombinant antigen |
00204-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HLTV-I p24 core recombinant antigen. |
HTLV-I p24 core recombinant antigen |
00204-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HLTV-I p24 core recombinant antigen. |
HLTV-I p24 core recombinant antigen. |
00204-V-100ugvial |
Virogen |
100 ug/vial |
EUR 150 |
|
Description: HLTV-I p24 core recombinant antigen. |
Feline Immunodeficiency Virus p24 gag Antigen (FIV p24 gag) Antibody |
abx413943-025mg |
Abbexa |
0.25 mg |
EUR 811.2 |
|
HIV-1 gag p17, p24 Protein |
20-abx260277 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1930.80
|
|
|
HIV-1 p24, 24 kDa Protein |
20-abx263118 |
Abbexa |
-
EUR 1562.40
-
EUR 393.60
-
EUR 276.00
|
|
|
Recombinant HIV-1 gag p17, p24 |
7-07675 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 gag p17, p24 |
7-07676 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 gag p17, p24 |
7-07677 |
CHI Scientific |
1000µg |
Ask for price |
HIV-1 p24 Core, Sf9 Protein |
20-abx260012 |
Abbexa |
-
EUR 2815.20
-
EUR 493.20
-
EUR 276.00
|
|
|
Toxoplasma gondii P24 (GRA1) recombinant antigen |
00207-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen |
Toxoplasma gondii P24 (GRA1) recombinant antigen |
00207-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen |
Toxoplasma gondii P24 (GRA1) recombinant antigen |
00207-V-100ugvial |
Virogen |
100ug/vial |
EUR 150 |
|
Description: Toxoplasma gondii P24 (GRA1) recombinant antigen |
Recombinant HIV-1 p24 His Tag |
7-07606 |
CHI Scientific |
5µg |
Ask for price |
Recombinant HIV-1 p24 His Tag |
7-07607 |
CHI Scientific |
20µg |
Ask for price |
Recombinant HIV-1 p24 His Tag |
7-07608 |
CHI Scientific |
1mg |
Ask for price |
Recombinant HIV-1 p24 Core, Sf9 |
7-07602 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 p24 Core, Sf9 |
7-07600 |
CHI Scientific |
2µg |
Ask for price |
Recombinant HIV-1 p24 Core, Sf9 |
7-07601 |
CHI Scientific |
10µg |
Ask for price |
HIV-1 gp120 and gp41 Chimeric Antigen (43 kDa, Detection) |
DAGF-223 |
Creative Diagnostics |
1mg |
EUR 817.2 |
HIV-1 p24, Biotin Labeled Protein |
20-abx260358 |
Abbexa |
-
EUR 1496.40
-
EUR 560.40
-
EUR 2364.00
|
|
|
p24-HIV(p24/661) Antibody |
BNCA0661-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against p24-HIV(p24/661), APC conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC800661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC800661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC810661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC810661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC940661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC940661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC700661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC700661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC880661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC880661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC050661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC050661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC040661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC040661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC400661-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC400661-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL |